Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1130245

	registered interest
	date	05/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Rheumatology: Nurses
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what steps they are taking to increase the number of training opportunities for rheumatology specialist nurses in England.
	tabling member printed	Baroness Masham of Ilton
	uin	HL16106
	answer	answer is ministerial correction date of answer 18/06/2019 answer text <p>It is for local National Health Service organisations with their knowledge of the healthcare needs of their local population to invest in post registration training for specialist skills and to deploy specialist nurses. The Nursing and Midwifery Council does not require a specific post-registration education programme to be undertaken in order for a Registered Nurse to become a Rheumatology Specialist Nurse.</p><p>The Department is making significant investment in nurse training, putting in place a range of measures to increase nursing workforce supply and support recruitment, including additional clinical placement funding to make available 5,000 more nurse training places each year and introducing Nurse Degree and Nursing Associate apprentices.</p> answering member printed Baroness Blackwood of North Oxford question first answered 18/06/2019 13:06:08 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1850 label Biography information for Baroness Masham of Ilton

1130247

	registered interest
	date	05/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the Written Answers by Baroness Blackwood of North Oxford on 22 May (HL15599 and 15600), which innovative vaccination schedules have been introduced following the Joint Committee on Vaccination and Immunisation's advice, including when a dose has been removed from an established programme.
	tabling member printed	Baroness Masham of Ilton
	uin	HL16108
	answer	answer is ministerial correction date of answer 18/06/2019 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) is the Government’s independent expert advisory body and its advice has always previously been followed.</p><p>The United Kingdom frequently adopts innovative immunisation schedules and we regularly change the vaccine schedule following the advice of the JCVI.</p><p>The JCVI advised that a two-dose schedule for the infant pneumococcal conjugate vaccine Prevenar13 is appropriate for the UK in place of the current three-dose schedule.</p><p>The JCVI’s advice was given full consideration, taking into account the potential public health implications, such as impact on cases of pneumococcal disease, before a decision was made to implement it. The evidence shows that two doses will sustain the results we have already seen. The decision is based on the excellent effectiveness of the vaccine and years of high uptake, which has helped to provide protection to the rest of the population and has successfully controlled many types of pneumococcal disease in this country.</p><p>We are confident that the world-class disease surveillance system we have in this country means our expert committee can closely monitor the impact of this change.</p> answering member printed Baroness Blackwood of North Oxford question first answered 18/06/2019 12:30:18 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1850 label Biography information for Baroness Masham of Ilton

1130248

	registered interest
	date	05/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pneumococcal Diseases: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the Written Answers by Baroness Blackwood of North Oxford on 22 May (HL15599 and HL15600), what plans they have to carry out a formal public consultation before implementing a 1+1 vaccine schedule in the UK.
	tabling member printed	Baroness Masham of Ilton
	uin	HL16109
	answer	answer is ministerial correction date of answer 18/06/2019 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) provides independent expert advice on the United Kingdom immunisation programme. It bases its recommendations on review of a wide range of scientific and other evidence, including from the published literature, and commissioned studies such as independent analyses of vaccine effectiveness and cost effectiveness. It can consult with stakeholders on its advice when it deems this necessary.</p><p>Between January and April 2018, the JCVI undertook a focused stakeholder consultation on its proposed advice about a change to the UK’s childhood pneumococcal conjugate vaccine schedule. The JCVI is well placed to carry out stakeholder consultation to ensure the latest and most appropriate evidence has been considered on potential changes to scheduling within the vaccine programme, including identifying who to target to obtain the evidence it needs to inform its advice. It is the JCVI rather than the Government that is best placed to carry out consultation about scheduling within the vaccine programme and who to target the consultation at.</p> answering member printed Baroness Blackwood of North Oxford question first answered 18/06/2019 12:51:32 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1850 label Biography information for Baroness Masham of Ilton

1130615

	registered interest
	date	06/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pneumococcal Diseases: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the Written Answers by Baroness Blackwood of North Oxford on 22 May (HL15599 and HL15600), whether they will place a copy of the Public Health England modelling on the estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales, presented at the 37th annual meeting of the European Society for Paediatric Infectious Diseases, in the Library of the House.
	tabling member printed	Baroness Masham of Ilton
	uin	HL16159
	answer	answer is ministerial correction date of answer 18/06/2019 answer text <p>The modelling by Public Health England (PHE) on the estimated impact of revising the pneumococcal conjugate vaccine schedule from 2+1 to 1+1 has been accepted for publication by Public Library of Science (PLoS) Medicine and is due to be published shortly. Release of the modelling data prior to its publication could prejudice publication.</p><p>The poster<em> Estimated impact of revising the 13-valent pneumococal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: a modelling study,</em> presented by PHE at the European Society for Paediatric Infectious Diseases, provides context for the model on additional invasive pneumococcal disease cases, pneumococcal community acquired pneumonia cases and deaths. A copy of the poster is attached.</p><p>More detail will be available once the published paper is available.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16160 question first answered 18/06/2019 12:28:36 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name PHE_poster.pdf title PHE_poster
	tabling member	1850 label Biography information for Baroness Masham of Ilton

1130616

	registered interest
	date	06/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pneumococcal Diseases: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, further to the Written Answers by Baroness Blackwood of North Oxford on 22 May (HL15599 and HL15600) and the Public Health England modelling on the estimated impact of revising the 13-valent pneumococcal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales, presented at the 37th annual meeting of the European Society for Paediatric Infectious Diseases, how many additional (1) invasive pneumococcal disease cases, (2) pneumococcal community acquired pneumonia cases, and (3) deaths, they predict as a result of a change to a 1+1 vaccine schedule over the next five years.
	tabling member printed	Baroness Masham of Ilton
	uin	HL16160
	answer	answer is ministerial correction date of answer 18/06/2019 answer text <p>The modelling by Public Health England (PHE) on the estimated impact of revising the pneumococcal conjugate vaccine schedule from 2+1 to 1+1 has been accepted for publication by Public Library of Science (PLoS) Medicine and is due to be published shortly. Release of the modelling data prior to its publication could prejudice publication.</p><p>The poster<em> Estimated impact of revising the 13-valent pneumococal conjugate vaccine schedule from 2+1 to 1+1 in England and Wales: a modelling study,</em> presented by PHE at the European Society for Paediatric Infectious Diseases, provides context for the model on additional invasive pneumococcal disease cases, pneumococcal community acquired pneumonia cases and deaths. A copy of the poster is attached.</p><p>More detail will be available once the published paper is available.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16159 question first answered 18/06/2019 12:28:37 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name PHE_poster.pdf title PHE_poster
	tabling member	1850 label Biography information for Baroness Masham of Ilton